[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2017[J].CA Cancer J Clin, 2017, 67(1):7-30.
[2] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66(2):115-132.
[3] 夏玲芳, 吴小华. 子宫内膜癌的手术治疗[J].中国实用妇科与产科杂志, 2017, 33(5):461-465.
[4] GERETTO M, PULLIERO A, ROSANO C, et al. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators[J].Am J Cancer Res, 2017, 7(6):1350-1371.
[5] SPITSCHAK A, MEIER C, KOWTHARAPU B, et al. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-kappaB to loss of the HES1/Notch1 regulatory circuit[J].Mol Cancer, 2017, 16(1):24-39.
[6] CHIANG C H, CHU P Y, HOU M F, et al. MiR-182 promotes proliferation and invasion and elevates the HIF-1alpha-VEGF-A axis in breast cancer cells by targeting FBXW7[J].Am J Cancer Res, 2016, 6(8):1785-1798.
[7] 安琪, 马晓欣. miRNA-302 c在子宫内膜癌组织中的表达及其与临床病理资料的关系[J].现代肿瘤医学, 2017, 25(1):127-130.
[8] 常香荣, 刘蓓蕾, 张海云. miR-520通过靶向调节BAMBI抑制肝星状细胞增殖的研究[J].现代医学, 2016, 44(11):1615-1620.
[9] 张姣, 宗毅, 沙晓峰, 等. Hsa-miR-29c在食管鳞状细胞癌中的表达及其临床意义[J].现代医学, 2014, 42(9):971-975.
[10] MYATT S S, WANG J, MONTEIRO L J, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer[J].Cancer Res, 2010, 70(1):367-377.
[11] QIN W, REN Q, LIU T, et al. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1[J].FEBS Lett, 2013, 587(9):1434-1439.
[12] NING T, ZHANG H, WANG X, et al. miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer[J].Tumour Biol, 2017, 39(6):1-13.
[13] LI Y, CHEN S, SHAN Z, et al. miR-182-5p improves the viability, mitosis, migration, and invasion ability of human gastric cancer cells by down-regulating RAB27A[J].Biosci Rep, 2017, 37(3):1-21.
[14] LIU Y, ZHANG B, SHI T, et al. miR-182 promotes tumor growth and increases chemoresistance of human anaplastic thyroid cancer by targeting tripartite motif 8[J].Onco Targets Ther, 2017, 10(2017):1115-1122.
[15] FASIHI-RAMANDI M, MORIDNIA A, NAJAFI A, et al. Inducing cell proliferative prevention in human acute promyelocytic leukemia by miR-182 inhibition through modulation of CASP9 expression[J].Biomed Pharmacother, 2017, 89(2017):1152-1158.
[16] LIU H, WANG Y, LI X, et al. Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1[J].Tumour Biol, 2013, 34(3):1713-1722.
[17] LIU Z, LIU J, SEGURA M F, et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma[J].J Pathol, 2012, 228(2):204-215.
[18] HUANG Y, FAN X X, TAO R, et al. Effect of miR-182 on hepatic fibrosis induced by schistosomiasis japonica by targeting FOXO1 through PI3K/AKT signaling pathway[J].J Cell Physiol, 2018, 2018(1):1-35.
[19] KIM K M, PARK S J, JUNG S H, et al. miR-182 is a negative regulator of osteoblast proliferation, differentiation, and skeletogenesis through targeting foxol[J].J Bone Miner Res, 2012, 27(8):1669-1679. |